» Articles » PMID: 36684047

Diagnostic Accuracy of the Multi-target Stool DNA Test in Detecting Colorectal Cancer: A Hospital-based Study

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The multi-target stool DNA test (MT-sDNA) has potential utility in the detection of colorectal cancer (CRC), but validation of its clinical accuracy has been limited in China.

Aim: To evaluate the diagnostic performance of MT-sDNA and investigate the combined diagnostic value of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 199 (CA199) with MT-sDNA in CRC and adenomas.

Methods: We evaluated the performance of the MT-sDNA kit based on a hospital clinical trial. In this case-control study, 135 participants from the Affiliated Hospital of Medical School of Ningbo University, including 51 CRC patients, 23 patients with adenomas, and 61 healthy controls were enrolled. We used a risk scoring system to determine the positivity of tests with histological diagnosis or colonoscopy as the reference standard.

Results: The main indices of sensitivity, specificity and accuracy were evaluated. The sensitivity and specificity for CRC detection were 90.2% and 83.3%, respectively, with an accuracy of 89.8%. For adenoma, the sensitivity and specificity were 56.5% and 68.9%, respectively, with an accuracy of 73.1%. The sensitivity and specificity of MT-sDNA combined with CEA in the diagnosis of adenoma were 78.3% and 60.7%, respectively.

Conclusion: The MT-sDNA test showed better performance in the detection of CRC, which was superior to AFP, CEA, and CA199 separately, but not for predicting adenomas. The combination of MT-sDNA with CEA further improved the sensitivity for adenoma diagnosis.

Citing Articles

Epidemiology and early screening strategies for colorectal cancer in China.

Yang Y, Gao Z, Huang A, Shi J, Sun Z, Hong H Chin J Cancer Res. 2024; 35(6):606-617.

PMID: 38204448 PMC: 10774140. DOI: 10.21147/j.issn.1000-9604.2023.06.05.


Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer.

Jiang H, Zhou S, Li G Front Pharmacol. 2023; 14:1189799.

PMID: 37719843 PMC: 10502318. DOI: 10.3389/fphar.2023.1189799.

References
1.
Mu J, Huang Y, Cai S, Li Q, Song Y, Yuan Y . Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia. Clin Chim Acta. 2019; 501:42-47. DOI: 10.1016/j.cca.2019.12.001. View

2.
Yang C, Wu W, Yang Y, Yang X, Sun J, Zhang W . Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening. Oncol Lett. 2020; 20(2):1193-1200. PMC: 7377198. DOI: 10.3892/ol.2020.11674. View

3.
Bosch L, Melotte V, Mongera S, Daenen K, Coupe V, van Turenhout S . Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. Am J Gastroenterol. 2019; 114(12):1909-1918. PMC: 6903367. DOI: 10.14309/ajg.0000000000000445. View

4.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

5.
Benson M, Johannes A, Weiss J, Lucey M, Pier J, Pfau P . Colorectal Cancer Screening After Changes in US Preventive Services Task Force Guidelines With Increased Screening Options. WMJ. 2021; 120(2):127-130. View